JP2024533487A5 - - Google Patents
Info
- Publication number
- JP2024533487A5 JP2024533487A5 JP2024516396A JP2024516396A JP2024533487A5 JP 2024533487 A5 JP2024533487 A5 JP 2024533487A5 JP 2024516396 A JP2024516396 A JP 2024516396A JP 2024516396 A JP2024516396 A JP 2024516396A JP 2024533487 A5 JP2024533487 A5 JP 2024533487A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- fusion polypeptide
- ferritin
- self
- fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163243402P | 2021-09-13 | 2021-09-13 | |
| US63/243,402 | 2021-09-13 | ||
| PCT/CA2022/051360 WO2023035083A1 (en) | 2021-09-13 | 2022-09-13 | Optimized multabody constructs, compositions, and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024533487A JP2024533487A (ja) | 2024-09-12 |
| JP2024533487A5 true JP2024533487A5 (enExample) | 2025-09-24 |
Family
ID=85506121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024516396A Pending JP2024533487A (ja) | 2021-09-13 | 2022-09-13 | 最適化されたＭｕｌｔａｂｏｄｙ構築物、組成物、及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240400704A1 (enExample) |
| EP (1) | EP4402179A4 (enExample) |
| JP (1) | JP2024533487A (enExample) |
| KR (1) | KR20240102943A (enExample) |
| CN (1) | CN118488971A (enExample) |
| AU (1) | AU2022343032A1 (enExample) |
| CA (1) | CA3231173A1 (enExample) |
| MX (1) | MX2024003140A (enExample) |
| WO (1) | WO2023035083A1 (enExample) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020320459A1 (en) * | 2019-08-01 | 2022-03-03 | The Governing Council Of The University Of Toronto | Multi-valent and multi-specific nanoparticle platforms and methods |
| CN117157328A (zh) * | 2021-01-28 | 2023-12-01 | 儿童医院 | Multabody构建体、组合物和方法 |
-
2022
- 2022-09-13 CN CN202280066146.9A patent/CN118488971A/zh active Pending
- 2022-09-13 MX MX2024003140A patent/MX2024003140A/es unknown
- 2022-09-13 AU AU2022343032A patent/AU2022343032A1/en active Pending
- 2022-09-13 CA CA3231173A patent/CA3231173A1/en active Pending
- 2022-09-13 KR KR1020247011820A patent/KR20240102943A/ko active Pending
- 2022-09-13 WO PCT/CA2022/051360 patent/WO2023035083A1/en not_active Ceased
- 2022-09-13 JP JP2024516396A patent/JP2024533487A/ja active Pending
- 2022-09-13 EP EP22865992.6A patent/EP4402179A4/en active Pending
- 2022-09-13 US US18/691,267 patent/US20240400704A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022544771A5 (enExample) | ||
| JP2022535924A5 (enExample) | ||
| US20170210818A1 (en) | Constant region antibody fusion proteins and compositions thereof | |
| JP2021514618A5 (enExample) | ||
| JP2021503455A5 (enExample) | ||
| JP2020114210A5 (enExample) | ||
| JP2019502694A5 (enExample) | ||
| US20180079798A1 (en) | Trispecific binding molecules for treating hbv infection and associated conditions | |
| JP2021500852A5 (enExample) | ||
| CN107206077A (zh) | 靶向g‑蛋白偶联受体的抗体和使用方法 | |
| JP2021522162A5 (enExample) | ||
| WO2019091436A1 (zh) | 4-1bb抗体及其制备方法和应用 | |
| JP2021159081A5 (enExample) | ||
| JP2011501951A5 (enExample) | ||
| JP2017504578A5 (enExample) | ||
| CA3173414A1 (en) | Pd-1 agonist multimeric binding molecules | |
| JP2011526249A5 (enExample) | ||
| JP2026004299A5 (enExample) | ||
| JP2024544559A5 (enExample) | ||
| JP2025541367A (ja) | 多価および多重特異性サイトカインアンタゴニスト | |
| JP2024533487A5 (enExample) | ||
| WO2025162161A1 (zh) | 特异性结合pd-1的单克隆抗体及其医药用途 | |
| JP2024533485A5 (enExample) | ||
| JP2022532994A5 (enExample) | ||
| RU2024109942A (ru) | Оптимизированные конструкции multabody, композиции и способы |